Pfizer named Cecile Guegan its permanent chief financial officer on Nov. 3, making the appointment effective Nov. 1 after she had led the finance function on an interim basis since August, Reuters and CNBC reported. She succeeds Dave Denton, who left Pfizer in August to become CFO of Nike. The move gives the drugmaker a permanent finance chief after several months of interim leadership.
Guegan’s appointment follows a search that considered internal and external candidates. The Pfizer board selected her unanimously, according to CFO Dive. Her interim period began after Denton’s departure, so the permanent decision keeps the company’s finance leadership with an executive already working in the role rather than introducing an outside hire at the top of the finance organization.
Guegan joined Pfizer in 2005 as finance director for Europe, the Middle East and Africa. She later moved through finance roles across the company’s businesses and became senior vice president of finance for its biopharmaceuticals group in 2022. That path gives her experience in both regional finance and a business unit whose portfolio includes medicines across multiple therapeutic areas. CNBC described her as having held several finance leadership roles over roughly two decades.
Chief Executive Albert Bourla cited Guegan’s company knowledge, industry experience and strategic vision when discussing the appointment, CFO Dive reported. Guegan said her focus would include disciplined capital allocation and targeted investment to support revenue growth. Those are priorities she named for the finance function; the coverage does not describe a new restructuring plan or a change in Pfizer’s broader leadership team beyond the CFO appointment.
The transition is a current role confirmation, not a succession date still waiting on a future board vote. It became effective Nov. 1, two days before the public announcement. That gives readers a precise date for when responsibility moved to Guegan. The appointment gives the company continuity from the August interim period while confirming who holds the permanent title. Readers can compare it with Encafeinados’ recent report on Keysight naming Jason Kary as its next CFO, another company setting out a named finance handoff. The two decisions are separate, but each makes the person responsible for finance visible before the next phase of corporate planning begins.
